Diamyd Medical
Diamyd Medical AB (Stockholm NASDAQ, First North) is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes.[1] The company's investigational drug retogatein is based on a recombinant form of GAD65, one of two human glutamate decarboxylase gene products.[1]
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression.[1][2]
Patents
Information here is NOT comprehensive as it depends on news items rather than patent database information extraction.
In 2026, Diamyd received notice that it would be granted a patent in Japan for antigenic treatment of Type I diabetes patients carrying the HLA DR4-DQ8 haplotype.[3] In the United States, the firm received notice it would be granted a methodological patent for alum-based intralymphatic retogatein (one of the company's investigaional drugs) admnistration.[4]
External links
References
- 1 2 3 "Diamyd Medical's facility achieves GMP certification". BioStock. Sweden. May 21, 2026. Retrieved June 26, 2026.
- ↑ "Annual Report 2021/2022" (PDF). Diamyd Medical AB. Retrieved 20 February 2023.
- ↑ "Diamyd Medical to receive patent approval in Japan". MarketScreener. Surperformance. March 19, 2026. Retrieved June 26, 2026.
- ↑ "Diamyd Medical secures US patent for intralymphatic Type 1 diabetes immunotherapy approach". allsci. Maryland, United States. February 10, 2026. Retrieved June 26, 2026.